Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory Renal medullary carcinoma
[vc_row][vc_column][vc_column_text css=""] Background: Some aggressive cancers have missing genes in their tumors, specifically SMARCB1 or SMARCA4. These types of tumors are often harder to treat and may not respond well to standard therapies. This study is testing two immunotherapy drugs: Tiragolumab blocks a protein called TIGIT, which activates the...
Effectiveness of Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
[vc_row][vc_column][vc_column_text css=""] Background: Nivolumab (Opdivo®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. This drug stimulates the immune system to attack any cancer cells that remain by targeting a molecule called PD-1. The Trial: This trial will investigate whether adding nivolumab...
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
[vc_row][vc_column][vc_column_text css=""] Background: Past research has found that certain features of Wilms tumor—such as its size, biology, or response to treatment—can help predict the risk of relapse. Using this information, a variety of suitable chemotherapy drug combinations will be used in this study: Vincristine stops cancer cells from...
Stereotactic Radiation Therapy (SABR) With or Without Immunotherapy for Patients With Unresectable or Metastatic Kidney Cancer (SAMURAI)
[vc_row][vc_column][vc_column_text css=""] Background: Stereotactic body radiation therapy (SABR) is a type of radiation therapy that uses special equipment to deliver radiation to tumors with high precision. This method may kill tumor cells with few radiation doses over a shorter period, causing less damage to normal tissue. Immunotherapy, such...
A Study of BMS-986488 as Monotherapy and Combination Therapy in Patients with Advanced Malignant Tumors
[vc_row][vc_column][vc_column_text css=""] Background: BMS-986488 is an investigational drug being studied for its safety, tolerability, and potential anti-cancer effects. It is being tested in combination with other cancer therapies. Nivolumab (Opdivo®) is an immunotherapy that works by boosting the body's immune system to recognize and attack cancer cells. Since this...
A Study of MDNA11 Alone or in Combination with Pembrolizumab in Patients with Advanced Kidney Cancer
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. MDNA11 is an experimental cancer therapy that...
A Study of Belzutifan + Lenvatinib + Pembrolizumab versus Lenvatinib + Pembrolizumab for Patients with Advanced Kidney Cancer
Background: Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor (TKI) that prevents the growth of cancer cells by blocking the formation of new blood vessels in tumours. It is similar to other approved medications such as Sunitinib (Sutent®) or Axitinib (Inlyta®). Pembrolizumab (Keytruda®) is an immunotherapy drug that is...
A Study of Belzutifan + Pembrolizumab versus Pembrolizumab Alone for Patients with Advanced Kidney Cancer
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targeting a molecule called PD-1 to reactivate the body’s own immune response to target and destroy cancer cells. Belzutifan (Welireg®) is a drug that is...
A Study of Combination Durvalamab + Savolitinib versus Sunitinib or Durvalamab Alone in Patients with Papillary Kidney Cancer
Background: Durvalamab (Imfinzi®) is a Health Canada approved immunotherapy that is currently used in the treatment of lung cancer, but is similar to another drug called Atezolizumab (Tecentriq®) which is already approved for the treatment of Kidney Cancer in Canada. These drugs work by targeting a...
A Study of Different Immune and Targeted Therapies for 1st Line Treatment of Kidney Cancer (Substudy 03A)
Background: Pembrolizumab (Keytruda®) is an immunotherapy drug that is already approved for the treatment of kidney cancer in Canada. It works by targetting a molecule called PD-1 to reactivate and strengthen the body’s immune response against cancer cells. Lenvatinib (Lenvima®) is a type of tyrosine kinase inhibitor (TKI)...
A Study of Combination Chemotherapy in Patients with Wilms Tumours
Background: Wilms tumour is a rare type of kidney cancer that primarily affects children. For most patients, the first line of treatment is surgery to remove the affected kidney (nephrectomy). This may be accompanied by either radiation treatment, chemotherapy, or both, depending on the size and...
A Study on Preventing Toxicity in Kidney Cancer Patients Using Fecal Transplantation (PERFORM)
Background: The term "microbiome" refers to all of the microorganisms (including bacteria, fungi, and other living things) that live inside and on the surface of the human body. There is growing evidence that suggests the microbiome plays a large role in our overall health and wellbeing....
Stereotactic Body Radiation Therapy (SBRT) with Ipilimumab and Nivolumab for Advanced Kidney Cancer (CYTOSHRINK)
Background: Stereotactic Body Radiation Therapy (SBRT) is used to treat cancers using substantially higher doses of radiation than conventional radiotherapy. This technology is able to deliver higher doses of radiation to a tumour, while limiting the dose of radiation to nearby normal tissues. The drugs used in...